# Stemona Alkaloid-Inspired Chemical Libraries: Methodology

# Development, Screening, and the Discovery of a Potent

# Class of Sigma Ligands

Kevin J. Frankowski, Vincent Setola<sup>+</sup>, Jon M. Evans<sup>+</sup>, Ben Neuenswander, Bryan L. Roth<sup>+</sup> and

Jeffrey Aubé\*

Department of Medicinal Chemistry, University of Kansas, Delbert M. Shankel Structural Biology Center, 2121 Simons Drive, Lawrence, Kansas 66047

† Department of Pharmacology School of Medicine and NIMH Psychoactive Drug Screening Program CB 7365, University of North Carolina Chapel Hill, 4072 Genetic Medicine Building, Chapel Hill, NC 27514

\*jaube@ku.edu

Contents:

Structures of the analogues profiled in Figure 3 of the manuscript
Heatmap table (secondary binding data) for compounds 10{7}, 10{20}, 10{22}
Full table of chemotype 14 analogues synthesized and known secondary binding data
Heatmap table (secondary binding data) for compounds 14{41} - 14{44}
General experimental details
Synthesis and derivatization of tricylic amine 9
Isocyanide multicomponent reaction derivatization of ketoamide tricyles 8
<sup>1</sup> H and <sup>13</sup> C NMR spectra for amine derivatives <b>10</b> and <b>11</b>

<sup>1</sup> H and <sup>13</sup> C NMR spectra for spirocyclic derivatives <b>14</b>	S-92	
References	S-103	

Structures of the Initial 104 Stemona alkaloid analogues screened<sup>a, b</sup>

<sup>a</sup> Binding data can be found in Figure 3 of the manuscript (heatmap format) and in the supporting information data set (numerical Ki values with structures)
<sup>b</sup> To correlate the structures left to right in rows

Reductive Amination Library Compounds:



Indole Library Compounds:



#### Quinoline Library Compounds:



Core Scaffold Analogue Compounds:



Carbamate Library Compounds:



<b>Profile screening</b>	(secondary	binding	data) for	compounds	10{7}.	10{20}	. 10{22}
I I Ollie Sel cening	(secondary	~ manns	<i>unun</i> , 101	compounds	- · ( ′ ) ,	<b>1</b> ( <b>1</b> )	, <b>-</b> ( <i></i> )

CMPD	5-HT1A	5-HT1B	5-HT1D	5-HT1E	5-HT2A	5-HT2B	5-HT2C	5-HT3	5-HT5A	5-HT6	5-HT7	Alpha1A	Alpha1B
10{7}	_	-		-		-					-		
10{20}	3,503.00												
10{22}	4,500.00												
<b>SWDD</b>	Alpha1D	Alpha2A	Alpha2B	Alpha2C	Beta1	Beta2	Beta3	D2	D4	DAT	DOR	H1	H2
10{7}		<u>1,271.00</u>	<u>6,433.00</u>	<u>978.1</u>					<u>1,103.00</u>			<u>1,250.00</u>	<u>7,971.00</u>
10{20}		<u>906.7</u>	<u>8,222.00</u>	<u>1,060.00</u>					<u>1,274.00</u>			<u>1,574.00</u>	
10{22}													
CMPD	H3	KOR	M1	M2	M3	M4	M5	MOR	NET	SERT	Sigma 1	Sigma 2	
10{7}					<u>2,686.00</u>			<u>516.9</u>		<u>1,941</u>	<u>5.8</u>	<u>124</u>	
10{20}		<u>1,115.00</u>			<u>6,492.00</u>			<u>736.6</u>			<u>2</u>	<u>174.9</u>	
10{22}											<u>12</u>	<u>288.1</u>	
Key:		Ki > 10 $\mu$ M or primary screen missed			Ki = 5 to 10	μΜ		Ki = 1 to 5	μM				
		Ki = 0.5 to 1 μM			Ki < 0.5 μM			no data or incomplete data					

Synthesis and known secondary binding data for analogues 14



entry	ketone	isocyanide	diamine	yield <sup>a</sup>	other known	Sigma 1 Ki	Sigma 2 Ki
	scaffold	fragment	fragment	(%)	binding Ki (nM)	(nM)	(nM)
1	8a	12a	<b>13</b> a	29		3,037	> 10,000
2	<b>8</b> a	12a	13b	27		> 10,000	> 10,000
3	<b>8</b> a	12a	13c	30	KOR 2,948	> 10,000	> 10,000
4	8a	12a	13d	7		> 10,000	no data
5	8a	12a	13e	23		> 10,000	no data
6	<b>8</b> a	12b	<b>13</b> a	43		> 10,000	> 10,000
7	<b>8</b> a	12b	13b	16		3,885	> 10,000
8	<b>8</b> a	12b	13c	57		> 10,000	> 10,000
9	8a	12b	13d	30		> 10,000	760
10	<b>8</b> a	12b	13e	41	KOR 607	1,325	476
11	<b>8</b> a	12c	<b>13</b> a	33		867	280
12	<b>8</b> a	12c	13b	51		5,907	2,152
13	<b>8</b> a	12c	13c	40		1,117	> 10,000
14	8a	12c	13d	32	KOR 802	623	> 10,000
15	8a	12c	13e	54	KOR 407	1,158	> 10,000
16	8a	12d	<b>13</b> a	29		949	> 10,000
17	8a	12d	13b	8		> 10,000	no data
18	8a	12d	13c	6		> 10,000	no data
19	8a	12d	13d	7		> 10,000	no data
20	8a	12d	13e	35		> 10,000	> 10,000
21	8b	12a	<b>13</b> a	17		> 10,000	3,868

22	8b	12a	13b	45		6,613	> 10,000
23	8b	12a	13c	50		> 10,000	7,569
24	8b	12a	13d	15	KOR 3,614	> 10,000	3,160
25	8b	12a	13e	40		9,143	> 10,000
26	8b	12b	13a	42	5HT <sub>1A</sub> 431	4,415	6,798
27	8b	12b	13b	44	KOR 5,877	2,538	7,349
28	8b	12b	13c	60		> 10,000	4,137
29	8b	12b	13d	46		> 10,000	2,245
30	8b	12b	13e	61		> 10,000	> 10,000
31	8a	12c	13a	40	KOR 5,641	> 10,000	> 10,000
32	8b	12c	13b	27		> 10,000	> 10,000
33	8b	12c	13c	55	KOR 2,945	> 10,000	> 10,000
34	8b	12c	13d	28	KOR 7,412	3,628	1,622
35	8b	12c	13e	53		1,507	917
36	8b	12d	1 <b>3</b> a	24		4,133	1,014
37	8b	12d	13b	6		> 10,000	> 10,000
38	8b	12d	13c	24		1,253	769
39	8b	12d	13d	14		4,009	778
40	8b	12d	13e	35		3,744	749
41	8b	12e	13b	69	Alpha1A 1,156	> 10,000	> 10,000
					Alpha1B 7,588		
42	8b	12e	13c	73	D2 9,360	> 10,000	> 10,000
43	8b	12e	13d	23	KOR 3,080	> 10,000	7,526

					Alpha1A 922		
					D2 3,530		
					D3 7,037		
44	8b	12e	13e	71	D2 8,170	> 10,000	> 10,000

(a) Yield refers to isolated material of the major isomer, when chromatographic separation

was possible



# Heatmap format of GPCR profile screening of compounds 14<sup>a</sup>

(a) Numerical data (K<sub>i</sub> values) included in above table

# **Experimental Details:**

**General.** All chemicals were used as purchased from commercial suppliers unless otherwise stated. Methylene chloride, ethyl ether, toluene, acetonitrile and THF were dried by being passed through two packed columns of basic alumina under argon pressure prior to use. The azide-containing diene precursor to 7 and the ketoamide substrates **8a** and **8b** were synthesized as previously described.<sup>i</sup> The synthetic routes and representative characterization for the compounds in Table 2 of the manuscript have been previously described.<sup>i</sup>

Parallel syntheses were performed on the Bohdan Miniblock XT parallel solution phase synthesizer obtained from Mettler-Toledo Auto Chem. Automated weighing was performed using the Bohdan Balance Automator (Mettler-Toledo Auto Chem). Parallel evaporation was performed on the GeneVac EZ-2 plus evaporator system. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400 and 100 MHz respectively) in CDCl<sub>3</sub> with 0.03% TMS as an internal standard. Chemical shifts are reported in parts per million (ppm) downfield from TMS. <sup>13</sup>C multiplicities were determined with the aid of an APT pulse sequence, differentiating the signals for methyl and methane carbons as "d" from methylene and quarternary carbons as "u". The infrared (IR) spectra were acquired as thin on a PerkinElmer Spectrum 100 FT-IR spectrometer equipped with a universal ATR sampling accessory and the absorbtion frequencies are reported in cm<sup>-1</sup>. Melting points were determined on an Electrothermal Mel-Temp model number 101D apparatus and are uncorrected.

HPLC analysis was carried out using an XBridge MS C-18 column (5  $\mu$ M, 4.6 × 150 mm) with gradient elution (5% CH<sub>3</sub>CN to 100% CH<sub>3</sub>CN) on a Waters Alliance 2795 Separation Module with a Waters 2996 Photodiode Array UV detector and a Waters/Micromass LCT Premier (TOF) detector. Purification was carried out using an XBridge MS C-18 column (5  $\mu$ M, 19 × 150 mm) with gradient elution (a narrow CH<sub>3</sub>CN gradient was chosen based on the targets retention time from LCMS analysis of the crude sample) on a Mass Directed Fractionation instrument with a Waters 2767 sample manager, a Waters 2525 HPLC pump, a Waters 2487 dual  $\lambda$  absorbance detector, and a Waters/Micromass ZQ (quadrupole) detector. Fractions were triggered using an MS and/or UV threshold determined by an LCMS analysis of the crude sample. One of three aqueous mobile phases were chosen for both analysis and purification to promote the

S-9

targets neutral state (water, 0.05% formic acid or pH 9.8 1mM HCO<sub>2</sub>NH<sub>4</sub>). High resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Premier (TOF instrument).

Radio ligands for the radio ligand binding assays were purchased from Perkin-Elmer or GE Healthcare. Competition binding assays were performed using transfected or stably expressing cell membrane preparations as previously described.<sup>ii, iii, iv</sup> Detailed information such as radioligand identity, radioligand concentration, incubation buffer and incubation time for all assays are available online (<u>http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf</u>).



**10-Ethyloctahydroazepino[3,2,1-hi]indole-4,9(1H,51H)-dione 7**. To a solution of 2cyclohexen-1-one (840 mg, 8.73 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and flame-dried 4 Å molecular sieve pellets (14.00 g) at -78 °C was added BF<sub>3</sub>•OEt<sub>2</sub> (1.1 mL, 8.73 mmol, 1.0 equiv.). After stirring for 5 minutes at -78 °C, the azide-containing siloxydiene (3.13 g, 13.10 mmol, 1.5 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added portionwise over 15 minutes. The reaction was stirred overnight, slowly warming to rt. The reaction was worked up with saturated aqueous NH<sub>4</sub>Cl and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated and chromatographed to afford the bicyclic diketoazide intermediate (1.80 g, 6.84 mmol, 78% yield). TLC R<sub>f</sub> = 0.43 (25% EtOAc in hexanes); <sup>1</sup>H NMR  $\delta$  0.83 (t, *J* = 7.6 Hz, 3 H), 1.40-1.52 (m, 2 H), 1.64 (m, 1 H), 1.85 (m, 2 H), 1.92-2.08 (complex, 3 H), 2.19-2.34 (complex, 3 H), 2.49 (m, 2 H), 2.68 (dd, J = 11.1, 14.4 Hz, 1 H), 2.78 (m, 1 H), 2.92 (m, 1 H), 3.27 (m, 1 H), 3.36 (m, 1 H); <sup>13</sup>C NMR  $\delta$  d 11.9, 35.8, 42.3, 49.7, 55.1; u 19.7, 23.7, 25.3, 31.2, 41.3, 41.6, 49.2, 212.0, 213.0; IR 3397 (w), 2962 (s), 2876 (s), 2094 (s), 1715 (s), 1257 (s) cm<sup>-1</sup>; HRMS calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>] 264.1712, found 264.1724.



**6-Ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 9**. The diketoazide 7 (108 mg, 0.41 mmol) and polystyrene bound triphenyl phosphine (0.27 g resin, 0.82 mmol) in THF (8 mL) were stirred at rt for 14 h. The reaction was filtered through celite and concentrated. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and NaBH(OAc)<sub>3</sub> (174 mg, 0.82 mmol) was added as a solid. The reaction was stirred 4 h at rt and partitioned between NaOH (1 N, 15 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude product was purified by filtration through a short alumina column, eluting with 1:1 acetone: CH<sub>2</sub>Cl<sub>2</sub> to give the tricyclic amine **9** (65 mg, 0.29 mmol, 72% yield) as a yellow oil. R<sub>f</sub> = 0.04 (1:1 acetone: CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR  $\delta$  0.81 (t, *J* = 7.3 Hz, 3 H), 1.21 (m, 2 H), 1.36-1.75 (complex, 11 H), 1.82 (m, 1 H), 2.14-2.32 (m, 3 H), 2.75 (dt, *J* = 2.8, 11.9 Hz, 1 H), 3.11 (ddd, *J* = 2.5, 4.3, 12.1 Hz, 1 H); <sup>13</sup>C NMR  $\delta$  d 11.8, 42.3, 43.7, 46.1, 57.3, 61.0; u 19.6, 24.5, 29.2, 33.2, 34.3, 44.6,

46.5, 214.0; IR (neat) 2927, 2858, 1709 cm<sup>-1</sup>; HRMS calcd for  $C_{14}H_{24}NO [M + H]$  222.1858, obsd 222.1851.



General procedure for the reductive amination of tricycle 9: The aldehyde component (0.50 mmol, 2.5 equiv) was charged as a neat oil or powder into individual reaction tubes of a Bohdan Miniblock XT parallel solution phase synthesizer. To each reaction tube was added a solution of the tricyclic amine 9 (45 mg, 0.20 mmol) in dichloroethane (3 mL) and solid sodium triacetoxyborohydride (170 mg, 0.80 mmol, 4 equiv). The reaction was stirred at rt for 14 h, diluted with aqueous sodium hydroxide (1 N, 6 mL), transferred to hydrophobic phase separator tubes and extracted with  $CH_2Cl_2$  (2 × 3 mL). The combined organics were collected in a clean set of  $17 \times 110$  mm reaction tubes and evaporated under vaccum in parallel to afford the crude tertiary amine products.

To each of the above crude tertiary amine products was added a magnetic stir bar, MeOH (4 mL) and  $K_2CO_3$  (125 mg, 0.90 mmol, 4.5 equiv). The reactions were stirred for 16 h, filtered through fritted reaction tubes and evaporated under vacuum in parallel. The reaction residues were directly purified by mass-directed preparative HPLC purification to afford the pure epimerized tertiary amine products **10**.



**1-(2-(benzyloxy)ethyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***[1]*. The general procedure afforded **10***[1]* (30.8 mg, 0.087 mmol, 44% yield) as a viscous light brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (t, *J* = 8.0 Hz, 3 H), 1.02 (dq, *J* = 4.0, 12.0 Hz, 1 H), 1.12-1.35 (complex, 4 H), 1.40-1.69 (complex, 5 H), 1.84-2.04 (complex, 4 H), 2.14 (m, 2 H), 2.33 (dd, *J* = 4.0, 12.0 Hz, 1 H), 2.45 (m, 1 H), 2.76 (m, 1 H), 3.03 (m, 2 H), 3.59 (t, *J* = 8.0 Hz, 2 H), 4.51 (s, 2 H), 7.24-7.38 (complex, 5 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 24.5, 30.0, 31.3, 33.1, 48.8, 52.1, 53.5, 67.3, 73.2, 138.3, 210.7; d 11.2, 41.4, 44.7, 50.7, 56.1, 64.5, 127.5, 127.6 (× 2), 128.3 (× 2); IR (neat) 2928, 2859, 1709 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>34</sub>NO<sub>2</sub> ([M+H]<sup>+</sup>), 356.2590, found 356.2570.



ID CMC-34-066-D File KF070808L01b Date 08-Jul-2008 Time 08:42:30 Description MDF008449



**6-ethyl-1-phenethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***[2]*. The general procedure afforded **10***[2]* (20.9 mg, 0.064 mmol, 32% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (t, *J* = 8.0 Hz, 3 H), 1.07 (dt, *J* = 4.0, 12.0 Hz, 1 H), 1.19-1.38 (complex, 3 H), 1.44-1.72 (complex, 5 H), 1.87-2.25 (complex, 5 H), 2.36 (dd, *J* = 4.0, 12.0 Hz, 1 H), 2.51 (m, 1 H), 2.74 (m, 2 H), 2.91 (m, 2 H), 3.06 (td, *J* = 4.0, 12.0 Hz, 1 H), 7.16-7.22 (complex, 3 H), 7.29 (m, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 18.0, 24.7, 29.9, 30.7, 31.4, 33.3, 48.9, 52.6, 55.1, 140.5, 210.7; d: 11.2, 41.5, 44.7, 50.9, 56.2, 63.6, 126.0, 128.5 (× 2), 128.7 (× 2); IR (neat) 3398, 2932, 2859, 1710 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>22</sub>H<sub>32</sub>NO ([M+H]<sup>+</sup>), 326.2484, found 326.2464.



ID CMC-34-066-E File KF070808L02b Date 08-Jul-2008 Time 08:54:52 Description MDF008453



**6-ethyl-1-(3-phenylpropyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***{3}*. The general procedure afforded **10***{3}* (37.6 mg, 0.111 mmol, 55% yield) as a viscous orange oil. HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>34</sub>NO ([M+H]<sup>+</sup>), 340.2640, found 340.2464.



#### ID CMC-34-066-F File KF070808L03b Date 08-Jul-2008 Time 09:07:13 Description MDF008629

# 6-Ethyl-1-(4-methoxybenzyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{4}. The

general procedure afforded **10***{4}* (18.2 mg, 0.053 mmol, 27% yield) as a light yellow oil. HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>32</sub>NO<sub>2</sub> ([M+H]<sup>+</sup>), 342.2433, found 342.2419.



#### ID CMC-34-066-J File KF070808L06 Date 08-Jul-2008 Time 09:44:19 Description MDF008615

**1-(4-butoxybenzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***{5}*. The general procedure afforded **10***{5}* (33.9 mg, 0.088 mmol, 44% yield) as a viscous colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (t, *J* = 8.0 Hz, 3 H), 0.97 (t, *J* = 8.0 Hz, 3 H), 1.05-1.58 (complex, 11 H), 1.62-1.80 (complex, 4 H), 1.86-2.15 (complex, 5 H), 2.29 (d, *J* = 3.6 Hz, 1 H), 2.35 (m, 1 H), 2.84 (td, *J* = 3.6, 11.6 Hz, 1 H), 3.20 (d, *J* = 13.6 Hz, 1 H), 3.95 (t, *J* = 5.2 Hz, 2 H), 4.04 (d, *J* = 13.2 Hz, 1 H), 6.84 (d, *J* = 8.4 Hz, 2 H), 7.18 (d, *J* = 8.8 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 19.3, 24.6, 30.4, 31.4, 31.5, 33.1, 48.8, 52.5, 56.6, 67.6, 130.6, 158.1, 211.0; d: 11.2, 13.9, 41.6, 44.7, 50.9, 56.2, 65.0, 114.1 (× 2), 130.2 (× 2); IR (neat) 2930, 2862, 2789, 1710 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>38</sub>NO<sub>2</sub> ([M+H]<sup>+</sup>), 384.2903, found 384.2908.



#### ID CMC-34-066-K File KF070808L07 Date 08-Jul-2008 Time 09:56:39 Description MDF008540

# 6-Ethyl-5-oxododecahydro-1H-benzo[de]quinolin-1-yl)methyl)benzonitrile 10{6}. The

general procedure afforded 10/6} (28.1 mg, 0.084 mmol, 42% yield) as an orange oil. HRMS

(ESI) m/z calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O ([M+H]<sup>+</sup>), 337.2280, found 337.2256.

#### ID CMC-34-066-L File KF070808L08 Date 08-Jul-2008 Time 10:09:02 Description MDF008543





# 1-(4-(dimethylamino)benzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{7}.

The general procedure afforded **10**{7} (18.4 mg, 0.052 mmol, 26% yield) as an orange oil.

HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>35</sub>N<sub>2</sub>O ([M+H]<sup>+</sup>), 355.2749, found 355.2733.



ID CMC-34-066-M File KF070808L09 Date 08-Jul-2008 Time 10:21:23 Description MDF008617

**6-Ethyl-5-oxododecahydro-1H-benzo[de]quinolin-1-yl)methyl)phenyl)acetamide 10***{8}*. The general procedure afforded **10***{8}* (17.5 mg, 0.049 mmol, 25% yield) as a viscous brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (t, *J* = 7.2 Hz, 3 H), 1.07 (dt, *J* = 3.2, 11.2 Hz, 1 H), 1.19-1.47 (complex, 5 H), 1.55 (m, 2 H), 1.67 (m, 1 H), 1.89-2.22 (complex, 6 H), 2.17 (s, 3 H), 2.31 (dd, *J* = 3.6, 13.2 Hz, 2 H), 2.45 (m, 1 H), 2.84 (td, *J* = 3.2, 10.4 Hz, 1 H), 3.22 (d, *J* = 13.6 Hz, 1 H),

4.07 (d, J = 13.6 Hz, 1 H), 7.24 (d, J = 8.4 Hz, 2 H), 7.44 (d, J = 8.4 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 24.6, 30.4, 31.4, 31.4, 33.0, 48.8, 52.7, 56.7, 136.6, 168.2, 210.8; d: 11.2, 41.5, 44.7, 47.5, 50.8, 56.2, 65.2, 119.7 (× 2), 129.6 (× 2); IR (neat) 3307, 2935, 2860, 2791, 1707, 1670 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>35</sub>N<sub>2</sub>O ([M+H]<sup>+</sup>), 355.2749, found 369.2527.



1-(3-(benzyloxy)benzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{9}. The general procedure afforded 10{9} (34.6 mg, 0.083 mmol, 41% yield) as a sticky brown oil. HRMS (ESI) m/z calcd for C<sub>28</sub>H<sub>36</sub>NO<sub>2</sub> ([M+H]<sup>+</sup>), 418.2746, found 418.2732.



#### ID CMC-34-066-O File KF070808L11 Date 08-Jul-2008 Time 10:46:07 Description MDF008550

**1-(2,4-dichlorobenzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***{10}*. The general procedure afforded **10***{10}{(*31.6 mg, 0.083 mmol, 42% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.86 (t, *J* = 7.2 Hz, 3 H), 0.96-1.20 (m, 2 H), 1.27-1.71 (complex, 9 H), 1.85 (m, 1 H), 1.92-2.24 (complex, 6 H), 2.34 (dd, *J* = 3.6, 12.8 Hz, 1 H), 2.81 (td, *J* = 3.2, 11.2 Hz, 1 H), 3.28 (d, *J* = 15.2 Hz, 1 H), 4.08 (d, *J* = 15.2 Hz, 1 H), 7.21 (dd, *J* = 2.0, 8.4 Hz, 1 H), 7.34 (d, *J* = 2.0 Hz, 1 H), 7.53 (d, *J* = 8.4 Hz, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 18.0, 24.6, 30.6, 31.5, 33.2, 48.8, 53.7, 53.9, 132.5, 134.0, 136.8, 210.7; d: 11.2, 41.5, 44.7, 51.0, 56.2, 66.1, 126.8, 128.9, 131.2; IR (neat) 2928, 2859, 2797, 1711 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>21</sub>H<sub>28</sub>Cl<sub>2</sub>NO ([M+H]<sup>+</sup>), 380.1548, found 380.1541.



#### ID CMC-34-066-P File KF070808L12 Date 08-Jul-2008 Time 10:58:29 Description MDF008623



# 1-(4-Chloro-3-nitrobenzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{11}.

The general procedure afforded **10***{11}* (34.7 mg, 0.089 mmol, 44% yield) as a sticky brown oil. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>28</sub>ClN<sub>2</sub>O<sub>3</sub> ([M+H]<sup>+</sup>), 391.1788, found 391.1777.

#### ID CMC-34-066-Q File KF070808L13 Date 08-Jul-2008 Time 11:10:51 Description MDF008625





# 1-(5-Bromo-2,3-dimethoxybenzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one

10{12}. The general procedure afforded  $10{12}$  (24.3 mg, 0.054 mmol, 27% yield) as a sticky

orange oil. HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>33</sub>BrNO<sub>3</sub> ([M+H]<sup>+</sup>), 450.1644, found 450.1635.



#### ID CMC-34-066-R File KF070808L14 Date 08-Jul-2008 Time 11:23:13 Description MDF008558

# 1-(3-Bromo-4-hydroxy-5-methoxybenzyl)-6-ethyldecahydro-1H-benzo[de]quinolin-

**5(3a1H)-one 10***{13}*. The general procedure afforded **10***{13}* (3.7 mg, 0.008 mmol, 4% yield, 80% purity) as an orange oil. HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>31</sub>BrNO<sub>3</sub> ([M+H]<sup>+</sup>), 436.1487, found 436.1470.



#### ID CMC-34-066-S File KF070808L15 Date 08-Jul-2008 Time 11:35:35 Description MDF008560

**6-Ethyl-1-(pyridin-3-ylmethyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***[14]*. The general procedure afforded **10***[14]* (32.4 mg, 0.104 mmol, 52% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (t, J = 7.2 Hz, 3 H), 1.08 (dt, J = 3.6, 12.8 Hz, 1 H), 1.21-1.73 (complex, 9 H), 1.88-2.15 (complex, 6 H), 2.26 (m, 1 H), 2.33 (dd, J = 3.6, 13.2 Hz, 1 H), 2.82 (td, J = 2.8, 12.0 Hz, 1 H), 3.24 (d, J = 14.0 Hz, 1 H), 4.12 (d, J = 14.0 Hz, 1 H), 7.25 (dd, J = 4.8, 7.6 Hz, 1 H), 7.65 (td, J = 2.0, 7.6 Hz, 1 H), 8.49 (dd, J = 1.6, 4.8 Hz, 1 H), 8.53 (d, J = 2.0 Hz, 1 H),; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 24.5, 30.6, 31.4, 33.0, 48.7, 53.0, 54.7, 135.0, 210.6; d: 11.2, 41.4, 44.6, 50.9, 56.1, 65.3, 123.2, 136.4, 148.2, 150.2; IR (neat) 3400, 2932, 2859, 2792, 1709 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>20</sub>H<sub>29</sub>N<sub>2</sub>O ([M+H]<sup>+</sup>), 313.2280, found 313.2294.



#### ID CMC-34-066-T File KF070808L16b Date 10-Jul-2008 Time 09:56:20 Description MDF008563

6-Ethyl-1-(naphthalen-2-ylmethyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{15}.

The general procedure afforded **10***{15}* (21.0 mg, 0.058 mmol, 29% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.86 (t, J = 7.2 Hz, 3 H), 1.09 (m, 1 H), 1.28-1.60 (complex, 8 H), 1.68 (m, 1 H), 1.90-2.16 (complex, 6 H), 2.32 (dd, J = 3.6, 12.8 Hz, 1 H), 2.37 (m, 1 H), 2.89 (td, J = 3.2, 11.6 Hz, 1 H), 3.34 (d, J = 13.2 Hz, 1 H), 4.31 (d, J = 13.6 Hz, 1 H), 7.44-7.48 (m, 3 H), 7.72 (s, 1 H), 7.78-7.83 (m, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 18.0, 24.6, 30.5, 31.5, 33.1, 48.8, 53.0, 57.6, 132.6, 133.3, 137.1, 210.8; d: 11.2, 41.6, 44.8, 50.9, 56.2, 65.6, 125.5, 125.9, 127.3, 127.4, 127.6 (× 2), 127.8; 3397, 2930, 2858, 2793, 1710 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>32</sub>NO ([M+H]<sup>+</sup>), 362.2484, found 362.2486.



#### ID CMC-34-066-U File KF070808L17b Date 10-Jul-2008 Time 10:08:44 Description MDF008635

**6-Ethyl-1-(quinolin-4-ylmethyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***[16]*. The general procedure afforded **10***[16]* (34.7 mg, 0.096 mmol, 48% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.87 (t, J = 8.0 Hz, 3 H), 1.28-1.72 (complex, 8 H), 1.83-2.28 (complex, 8 H), 2.34 (dd, J = 4.0, 12.0 Hz, 1 H), 2.77 (td, J = 3.2, 11.6 Hz, 1 H), 3.47 (d, J = 15.2 Hz, 1 H), 3.74 (t, J = 6.8 Hz, 1 H), 4.65 (d, J = 14.4 Hz, 1 H), 7.53 (d, J = 4.0 Hz, 1 H), 7.55 (ddd, J = 1.2, 7.2, 8.0 Hz, 1 H), 7.71 (ddd, J = 1.2, 7.2, 8.4 Hz, 1 H), 8.12 (dd, J = 0.8, 8.4 Hz, 1 H), 8.28 (dd, J = 0.4, 8.0 Hz, 1 H), 8.85 (d, J = 4.4 Hz, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 24.6, 30.5, 31.4, 33.2, 48.7, 53.8, 54.8, 127.4, 146.2, 148.2, 210.7; d: 11.2, 41.5, 44.7, 51.0, 56.2, 66.6, 121.1, 123.8, 126.1, 129.0, 150.1; IR (neat) 3399, 2937, 2859, 2796, 1709 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>24</sub>H<sub>31</sub>N<sub>2</sub>O ([M+H]<sup>+</sup>), 363.2436, found 363.2424.



#### ID CMC-34-066-V File KF070808L18 Date 08-Jul-2008 Time 12:12:40 Description MDF008570

**6-ethyl-1-((1-methyl-1H-imidazol-2-yl)methyl)decahydro-1H-benzo[de]quinolin-5(3a1H)one 10***{17}*. The general procedure afforded **10***{17}* (26.1 mg, 0.083 mmol, 41% yield) as a viscous orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.85 (t, *J* = 7.6 Hz, 3 H), 1.05 (dt, *J* = 3.2, 13.2 Hz, 1 H), 1.16-1.28 (m, 2 H), 1.30-1.39 (m, 3 H), 1.47-1.59 (m, 3 H), 1.68 (m, 1 H), 1.87-2.18 (complex, 6 H), 2.32 (dd, *J* = 4.0, 12.8 Hz, 1 H), 2.33 (m, 1 H), 2.70 (td, *J* = 2.8, 11.6 Hz, 1 H), 3.34 (d, *J* = 13.6 Hz, 1 H), 3.72 (s, 3 H), 4.17 (d, *J* = 13.6 Hz, 1 H), 6.83 (d, *J* = 1.2 Hz, 1 H), 6.92 (d, *J* = 1.2 Hz, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 17.9, 24.5, 30.1, 31.4, 33.1, 48.7, 49.7, 52.8, 145.6, 210.6; d: 11.1, 33.0, 41.4, 44.5, 50.8, 56.1, 65.6, 121.4, 127.0; IR (neat) 3392, 2938, 2860, 1707 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>19</sub>H<sub>30</sub>N<sub>3</sub>O ([M+H]<sup>+</sup>), 316.2389, found 316.2376.



#### ID CMC-34-066-W File KF070808L19 Date 08-Jul-2008 Time 12:24:56 Description MDF008574

### 1-(Benzo[b]thiophen-2-ylmethyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one

**10***{18}*. The general procedure afforded **10***{18}* (25.9 mg, 0.070 mmol, 35% yield) as a viscous yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.84 (t, *J* = 7.2 Hz, 3 H), 1.03-1.12 (m, 1 H), 1.25-1.70 (complex, 9 H), 1.84-2.16 (complex, 5 H), 2.24-2.36 (m, 3 H), 2.99 (td, *J* = 3.2, 11.6 Hz, 1 H), 3.88 (d, *J* = 14.8 Hz, 1 H), 4.21 (dd, *J* = 0.8, 15.2 Hz, 1 H), 7.11 (d, *J* = 0.8 Hz, 1 H), 7.28-7.34 (m, 2 H), 7.69 (dd, *J* = 1.6, 7.2 Hz, 1 H), 7.78 (m, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 18.0, 24.5, 30.4, 31.4, 33.3, 48.8, 52.3, 53.0, 137.6, 139.7, 143.0, 210.7; d: 11.2, 41.4, 44.6, 51.0, 56.2, 64.1, 122.2, 122.4, 123.0, 123.8, 124.1; IR (neat) 3400, 2932, 2858, 2795, 1709 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>30</sub>NOS ([M+H]<sup>+</sup>), 368.2048, found 368.2034.



#### ID CMC-34-066-X File KF070808L20 Date 08-Jul-2008 Time 12:37:18 Description MDF008579

**1-Benzoyl-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 11***[19]*. The tricyclic amine (46 mg, 0.21 mmol), triethyl amine (63 mg, 0.62 mmol, 3.0 equiv.) and benzoyl chloride (58 mg, 0.42 mmol, 2.0 equiv.) were dissolved in THF (2.0 mL) then stirred at rt 16 h. The reaction mixture was diluted with 0.5 N HCL (3 mL) and extracted with EtOAc (2 × 3 mL). The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated and the residue purified by silica chromatography to yield the amide **11***[19]* (36 mg, 0.111 mmol, 53% yield) as a light orange oil.  $R_f = 0.58$  (1:1 acetone:CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR  $\delta$  0.87 (t, *J* = 7.2 Hz, 3 H), 1.10 (m, 2 H), 1.10-1.84 (complex, 11 H), 1.88-2.18 (complex, 3 H), 2.29 (m, 4 H), 2.47 (dd, *J* = 4.4 Hz, 1 H), 3.40-3.57 (m, 2 H), 7.40 (m, 5 H); <sup>13</sup>C NMR  $\delta$  d 11.3, 37.0, 45.7, 46.5, 56.0, 60.2, 126.9 (×2), 128.4 (×2), 129.5; u 17.9, 24.7, 29.7, 31.4, 32.1, 43.1, 49.0, 137.2, 171.7, 209.9; IR (neat) 2928, 2858, 1706, 1623 cm<sup>-1</sup>; HRMS calcd for C<sub>21</sub>H<sub>28</sub>NO<sub>2</sub> [M + H] 326.2120, obsd 326.2109.



#### ID CMC-34-065-B File KF070808L22 Date 08-Jul-2008 Time 08:17:45 Description MDF008585

# **1-Benzyl-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10***{20}*. The general procedure (adjusted for the new quantity of starting amine (47 mg, 0.21 mmol) and omitting the K<sub>2</sub>CO<sub>3</sub> epimerization step) afforded **10***{***20***}* (21 mg, 0.067 mmol, 32% yield) as a light yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) $\delta$ 0.81 (t, *J* = 7.6 Hz, 3 H), 1.19 (m, 1 H), 1.30-1.50 (complex, 6 H), 1.55 (m, 2 H), 1.68 (m, 2 H), 1.88 (m, 2 H), 2.03 (dt, *J* = 3.2, 12.0 Hz, 1 H), 2.13 (m, 1 H), 2.19-2.30 (m, 3 H), 2.86 (td, *J* = 3.6, 11.2 Hz, 1 H), 3.17 (d, *J* = 13.2 Hz, 1 H), 4.12 (d, *J* = 13.2 Hz, 1 H), 7.21-7.33 (complex, 5 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) $\delta$ u: 19.7, 24.8, 29.3, 30.4, 33.1, 44.6, 53.2, 57.4, 139.4, 214.2; d: 11.8, 42.5, 44.2, 44.9, 57.3, 66.3, 126.7, 128.1 (× 2), 129.0 (× 2); IR (neat) 2929, 2860, 1709, 1665 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>21</sub>H<sub>30</sub>NO ([M+H]<sup>+</sup>), 312.2327, found 312.2316.



#### ID CMC-34-051 File KF070808L23 Date 08-Jul-2008 Time 12:49:40 Description MDF008588



**6-Ethyl-1-(2,4,6-trifluorobenzyl)decahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{21}.** The general procedure (adjusted for the new quantity of starting amine (59 mg, 0.268 mmol) and omitting the K<sub>2</sub>CO<sub>3</sub> epimerization step) afforded **10{21}** (50 mg, 0.137 mmol, 51% yield) as a viscous light orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.79 (t, *J* = 7.6 Hz, 3 H), 1.25 (m, 1 H), 1.32-1.56 (complex, 7 H), 1.59-1.72 (m, 2 H), 1.85-1.94 (m, 2 H), 2.11 (m, 2 H), 2.18-2.29 (m, 2 H), 2.40 (dd, *J* = 3.2, 12.0 Hz, 2 H), 2.87 (d, *J* = 11.6 Hz, 1 H), 3.31 (d, *J* = 12.8 Hz, 1 H), 4.08 (d, *J* = 13.2 Hz, 1 H), 6.66 (q, *J* = 8.8, 7.6 Hz, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 19.6, 24.7,

29.2, 32.6, 43.3, 44.4, 52.2, 52.3, 214.2; d: 11.7, 42.2, 44.2, 44.6, 57.2, 66.1, 100.1 (m, 2 C); HRMS (ESI) *m/z* calcd for C<sub>21</sub>H<sub>27</sub>F<sub>3</sub>NO ([M+H]<sup>+</sup>), 366.2045, found 366.2019.



ID CMC-34-052 File KF070808L24 Date 08-Jul-2008 Time 13:02:02 Description MDF008589



**6-Ethyl-1-propyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 10{22}**. The general procedure (adjusted for the altered quantity of starting amine (30.6 mg, 0.138 mmol)) afforded **10{22}** (12.4 mg, 0.047 mmol, 34% yield) as a viscous yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.83 (t, *J* = 7.2 Hz, 3 H), 0.84 (t, *J* = 7.2 Hz, 3 H), 1.03 (m, 1 H), 1.10-1.34 (complex, 4 H), 1.39-1.56 (complex, 5 H), 1.60-1.67 (m, 2 H), 1.84-1.94 (m, 3 H), 2.01 (m, 1 H), 2.11 (m, 1 H), 2.31 (m, 2 H), 2.47 (m, 1 H), 2.65 (m, 1 H), 2.94 (m, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ u: 17.4, 17.9, 24.6, 29.9, 31.3, 33.3, 48.8, 52.5, 55.1, 210.8; d: 11.1, 12.0, 41.5, 44.7, 50.8, 56.1, 63.9; IR

(neat) 2960, 2933, 2869, 1709 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for  $C_{17}H_{30}NO$  ([M+H]<sup>+</sup>), 264.2327, found 264.2327.





# 1-(4-Bromobenzoyl)-6-ethyldecahydro-1H-benzo[de]quinolin-5(3a1H)-one 11{23}. The

tricyclic amine (32 mg, 0.15 mmol) and *p*-bromobenzoyl chloride were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) and pyridine (0.5 mL) and stirred at rt 16 h. The reaction mixture was concentrated and the residue purified by silica chromatography to yield the amide **11{23}** (37 mg, 0.092 mmol, 61% yield) as a light orange oil.  $R_f$  = 0.63 (1:1 acetone:CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR  $\delta$  0.84 (t, *J* = 7.3 Hz, 3 H), 1.26 (m, 2 H), 1.47 (m, 2 H), 1.55-1.77 (complex, 4 H), 1.80-1.92 (m, 4 H), 2.21-2.29 (m, 4 H), 3.34 (m, 2 H), 3.57 (m, 1 H), 7.30 (d, *J* = 8.6 Hz, 2 H), 7.54 (d, *J* = 8.3 Hz, 2 H); <sup>13</sup>C NMR  $\delta$  d

11.7, 38.8, 40.7, 45.0, 56.8, 62.1, 128.7, 131.7; u 19.6, 25.0, 29.1, 29.6, 32.4, 44.6, 44.9, 123.9, 136.1, 170.9, 212.8; IR (neat) 2930, 2858, 1707, 1629 cm<sup>-1</sup>; HRMS calcd for C<sub>21</sub>H<sub>27</sub>BrNO<sub>2</sub> [M + H] 404.1225, obsd 404.1230.



**General procedure A for the parallel synthesis of spiroheterocycles 14:** The reactions were performed in the 24-position Bohdan MiniBlock XT solution phase synthesis platform. Each tube of the MiniBlock platform was charged with a magnetic stirring bar, ketoamide **8a** (70 mg, 0.23 mmol), diamine fragment **13** (0.28 mmol, 1.2 equiv.) and *p*-toluenesulfonic acid (6 mg, 0.023 mmol, 0.1 equiv.). A solution of isonitrile **12** (0.28 mmol, 1.2 equiv.) in EtOH (2.0 mL)

was added via syringe through the septum and the reactions were stirred for 14 h at rt. Water (7 mL) was added to precipitate the products and the entire contents of each reaction tube was transferred to a fritted reaction tube in a second Miniblock platform. The collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL) then dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The organic soluble material was collected, the solvent removed in vacuo and the residue purified by mass-directed, reverse-phase HPLC purification.

**General procedure B for the parallel synthesis of spiroheterocycles 14:** The reactions were performed in the 24-position Bohdan MiniBlock XT solution phase synthesis platform. Each tube of the MiniBlock platform was charged with a magnetic stirring bar, ketoamide **8b** (70 mg, 0.34 mmol), diamine fragment **13** (0.41 mmol, 1.2 equiv.) and *p*-toluenesulfonic acid (6 mg, 0.034 mmol, 0.1 equiv.). A solution of isonitrile **12** (0.41 mmol, 1.2 equiv.) in EtOH (2.0 mL) was added via syringe through the septum and the reactions were stirred for 14 h at rt. Water (7 mL) was added to precipitate the products. The contents of each reaction tube was transferred to a fritted reaction tube in a second Miniblock platform. The collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL) then dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The organic soluble material was collected, the solvent removed in vacuo and the residue purified by mass-directed, reverse-phase HPLC purification.



**3'-(Cyclohexylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'quinoxalin]-4(31H)-one 14***{1}*. General procedure A afforded the spiroheterocycle **14***{1}* (26 mg, 0.066 mmol, 29% yield) as a tan solid. IR (neat) 3301, 2924, 2845, 1607, 1575 cm<sup>-1</sup>; HRMS (ESI) m/z calcd for C<sub>24</sub>H<sub>33</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 393.2654, found 393.2654.





#### 3'-(Cyclohexylamino)-7'-nitro-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-

ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{2}. General procedure A afforded the

spiroheterocycle 14{2} (27 mg, 0.062 mmol, 27% yield) as a reddish-brown solid. MP > 260 °C;

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.09 (m, 1 H), 1.25-1.49 (m, 3 H), 1.67-1.83 (complex, 4 H),

1.95-2.09 (complex, 4 H), 2.26 (m, 3 H), 2.62 (m, 1 H), 3.31 (quin, J = 2.0 Hz, 2 H), 3.52 (m, 2

H), 3.71-3.76 (complex, 4 H), 4.06 (m, 1 H), 7.03 (d, *J* = 8.4 Hz, 1 H), 7.50 (d, *J* = 2.4 Hz, 1 H),

7.62 (dd, J = 2.8, 8.8 Hz, 1 H; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  u: 26.2, 26.3, 26.5, 26.7, 27.4, 29.2, 32.6, 33.5, 33.6, 34.1, 44.1, 53.8, 68.9, 137.2, 143.4, 155.3, 171.5; d: 30.5, 38.6, 51.3, 60.3, 109.6, 116.3, 122.4; IR (neat) 3448, 3339, 3257, 2923, 2847, 1615, 1521, 1498, 1480 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>24</sub>H<sub>32</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 438.2505, found 438.2510.





# **7'-Chloro-3'-(cyclohexylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{3}*. General procedure A afforded the spiroheterocycle **14***{3}* (29 mg, 0.069 mmol, 30% yield) as a tan solid. HRMS (ESI) *m/z* calcd for $C_{24}H_{32}CIN_4O$ ([M+H]<sup>+</sup>) 427.2265, found 427.2264.


### ID CMC-34-157-A3 File KF090408L03 Date 04-Sep-2008 Time 12:24:12 Description MDF009334

# 6',7'-Dichloro-3'-(cyclohexylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{4}. General procedure A afforded the spiroheterocycle 14{4} (7 mg, 0.02 mmol, 7% yield) as a brown solid. HRMS (ESI) m/z calcd for $C_{24}H_{31}Cl_2N_4O$ ([M+H]<sup>+</sup>) 461.1875, found 461.1868.

#### ID CMC-34-157-A4 File KF090408L04 Date 04-Sep-2008 Time 12:36:32 Description MDF009337



**3'-(Cyclohexylamino)-6',7'-dimethyl-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{5}*. General procedure A afforded the spiroheterocycle **14***{5}* (22 mg, 0.052 mmol, 23% yield) as a tan solid. HRMS (ESI) *m/z* calcd for  $C_{26}H_{37}N_4O$  ([M+H]<sup>+</sup>) 421.2967, found 421.2955.



### ID CMC-34-157-A5 File KF090408L05 Date 04-Sep-2008 Time 12:48:52 Description MDF009341

## 3'-((2,4,4-Trimethylpentan-2-yl)amino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-

spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14[6]. General procedure A afforded the spiroheterocycle 14[6] (42 mg, 0.099 mmol, 43% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>39</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 423.3124, found 423.3115.



### ID CMC-34-157-B1 File KF090408L06 Date 04-Sep-2008 Time 13:01:11 Description MDF009344

# 7'-Nitro-3'-((2,4,4-trimethylpentan-2-yl)amino)-1,2,5,6,6a,7,9,9a-octahydro-1'Hspiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{7}. General procedure A afforded the spiroheterocycle 14{7} (17 mg, 0.036 mmol, 16% yield) as a red solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>38</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 468.2975, found 468.2980.



### ID CMC-34-157-B2 File KF090408L07 Date 04-Sep-2008 Time 13:13:31 Description MDF009349

7'-Chloro-3'-((2,4,4-trimethylpentan-2-yl)amino)-1,2,5,6,6a,7,9,9a-octahydro-1'Hspiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{8}. General procedure A afforded the spiroheterocycle 14{8} (60 mg, 0.13 mmol, 57% yield) as a brown solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>38</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 457.2734, found 457.2730.



### ID CMC-34-157-B3 File KF090408L08 Date 04-Sep-2008 Time 13:25:51 Description MDF009352

6',7'-Dichloro-3'-((2,4,4-trimethylpentan-2-yl)amino)-1,2,5,6,6a,7,9,9a-octahydro-1'Hspiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{9}. General procedure A afforded the spiroheterocycle 14{9} (34 mg, 0.070 mmol, 30% yield) as an orange solid. IR (neat) 3483, 3286, 2949, 2874, 1630, 1608, 1580, 1515, 1481 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for  $C_{26}H_{37}Cl_2N_4O$  ([M+H]<sup>+</sup>) 491.2344, found 491.2330.



### ID CMC-34-157-B4 File KF090408L09 Date 04-Sep-2008 Time 13:38:10 Description MDF009358

6',7'-Dimethyl-3'-((2,4,4-trimethylpentan-2-yl)amino)-1,2,5,6,6a,7,9,9a-octahydro-1'Hspiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{10}. General procedure A afforded the spiroheterocycle  $14{10}$  (42 mg, 0.093 mmol, 41% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>28</sub>H<sub>43</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 451.3437, found 451.3433.



### ID CMC-34-157-B5 File KF090408L10 Date 04-Sep-2008 Time 13:50:30 Description MDF009364

**3'-(Benzylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'quinoxalin]-4(31H)-one 14{11**}. General procedure A afforded the spiroheterocycle 14{11} (30 mg, 0.075 mmol, 33% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>29</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 401.2341, found 401.2329.



### ID CMC-34-157-C1 File KF090408L11 Date 04-Sep-2008 Time 14:02:50 Description MDF009367

**3'-(Benzylamino)-7'-nitro-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{12}*. General procedure A afforded the spiroheterocycle 14*{12}* (53 mg, 0.12 mmol, 51% yield) as a red solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 446.2192, found 446.2189.



### ID CMC-34-157-C2 File KF090408L12 Date 04-Sep-2008 Time 14:15:09 Description MDF009370

7'-Chloro-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{13}. General procedure A afforded the spiroheterocycle 14{13} (40 mg, 0.092 mmol, 40% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>28</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 435.1960, found 435.1960.



### ID CMC-34-157-C3 File KF090408L13 Date 04-Sep-2008 Time 14:27:28 Description MDF009374

**3'-(Benzylamino)-6',7'-dichloro-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{14}*. General procedure A afforded the spiroheterocycle **14***{14}* (34 mg, 0.073 mmol, 32% yield) as a brown solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 469.1562, found 469.1568.



### ID CMC-34-157-C4 File KF090408L14 Date 04-Sep-2008 Time 14:39:48 Description MDF009377

**3'-(Benzylamino)-6',7'-dimethyl-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{15}*. General procedure A afforded the spiroheterocycle **14***{15}* (53 mg, 0.12 mmol, 54% yield) as a yellow solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>33</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 429.2654, found 429.2643.



### ID CMC-34-157-C5 File KF090408L15 Date 04-Sep-2008 Time 14:52:08 Description MDF009380

**3'-(o-Tolylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'quinoxalin]-4(31H)-one 14***{16}*. General procedure A afforded the spiroheterocycle **14***{16}* (27 mg, 0.067 mmol, 29% yield) as a tan solid. Mp > 260 °C; ); <sup>1</sup>H NMR  $\delta$  0.91 (t, *J* = 13.2 Hz, 1 H), 1.19 (t, *J* = 13.2 Hz, 1 H), 1.65 (m, 1 H), 1.76 (m, 1 H), 1.96 (m, 2 H), 2.16 (s, 3 H), 2.19 (m, 1 H), 2.36 (m, 2 H), 2.89 (m, 1 H), 3.12 (m, 1 H), 3.51 (t, *J* = 10.4 Hz, 1 H), 3.64 (m, 2 H), 3.76 (m, 1 H), 6.47 (m, 1 H), 6.49 (m, 1 H), 6.69 (m, 2 H), 6.81 (m, 2 H), 7.02 (dt, *J* = 1.2, 7.4 Hz, 1 H), 7.20 (t, *J* = 7.6 Hz, 1 H), 7.24 (br s, 1 H); <sup>13</sup>C NMR  $\delta$  d 18.1, 29.1, 37.0, 59.7, 113.7, 114.9, 119.5, 120.6, 122.4, 123.4, 127.1, 131.1; u 25.5, 27.1, 27.9, 33.0, 35.3, 42.9, 55.2, 126.6, 129.5, 132.3, 146.3, 150.6, 169.0; IR (neat): 3319, 3270, 2942, 2874, 1659, 1601 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>29</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 401.2341, found 401.2334.



### ID CMC-34-157-D1 File KF090408L16 Date 04-Sep-2008 Time 15:04:28 Description MDF009384

7'-Nitro-3'-(o-tolylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{17}. General procedure A afforded the spiroheterocycle 14{17} (8 mg, 0.019 mmol, 8% yield) as a red-brown solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 446.2192, found 446.2187.



### ID CMC-34-157-D2 File KF090408L17 Date 04-Sep-2008 Time 15:16:47 Description MDF009389

7'-Chloro-3'-(o-tolylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{18}. General procedure A afforded the spiroheterocycle 14{18} (6 mg, 0.014 mmol, 6% yield) as a tan solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.90 (dt, *J* = 3.6, 12.8 Hz, 1 H), 1.19 (dt, *J* = 3.6, 13.2 Hz, 1 H), 1.65 (m, 1 H), 1.77 (m, 1 H), 1.85 (m, 1 H), 1.95 (m, 1 H), 2.15 (s, 3 H), 2.25-2.44 (m, 2 H), 2.88 (m, 1 H), 3.10 (m, 1 H), 3.51(t, *J* = 10.4 Hz, 1 H), 3.65 (m, 2 H), 6.39 (d, *J* = 8.8 Hz, 1 H), 6.46 (s, 1 H), 6.50 (d, *J* = 2.0 Hz, 1 H), 6.63 (m, 1 H), 6.78 (m, 1 H), 7.03 (t, *J* = 7.2 Hz, 1 H), 7.20 (t, *J* = 7.2 Hz, 1 H), 7.24 (s, 1 H); <sup>13</sup>C NMR  $\delta$  d 18.2, 29.1, 37.0, 40.1, 59.7, 114.5, 114.7, 119.3, 120.5, 123.6, 127.2, 131.3; u 25.5, 27.1, 27.9, 33.1, 35.6, 43.0, 55.3, 129.5, 130.9, 133.5, 145.9, 146.2, 150.2, 169.1; IR 3300, 3268, 2940, 1656, 1596, 1505 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>28</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 435.1960, found 435.1948.



### ID CMC-34-157-D3 File KF090408L18 Date 04-Sep-2008 Time 15:29:07 Description MDF009393

# 6',7'-Dichloro-3'-(o-tolylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1ij]quinoline-8,2'-quinoxalin]-4(31H)-one 14{19}. General procedure A afforded the spiroheterocycle 14{19} (8 mg, 0.017 mmol, 7% yield) as a brown solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 469.1562, found 469.1570.



### ID CMC-34-157-D4 File KF090408L19 Date 04-Sep-2008 Time 15:41:27 Description MDF009397

**6',7'-Dimethyl-3'-(o-tolylamino)-1,2,5,6,6a,7,9,9a-octahydro-1'H-spiro[pyrrolo[3,2,1-i]]quinoline-8,2'-quinoxalin]-4(31H)-one 14***{20}*. General procedure A afforded the spiroheterocycle **14***{20}* (34 mg, 0.080 mmol, 35% yield) as a tan solid. Mp > 260 °C; ); <sup>1</sup>H NMR  $\delta$  0.87 (t, *J* = 12.0 Hz, 1 H), 1.15 (t, *J* = 13.2 Hz, 1 H), 1.64 (dd, *J* = 6.8, 13.2 Hz, 1 H), 1.75 (m, 1 H), 1.90-2.01 (m, 3 H), 2.09 (s, 3 H), 2.14 (s, 3 H), 2.15 (s, 3 H), 2.18 (m, 2 H), 2.32 (m, 2 H), 2.87 (td, *J* = 3.6, 12.8 Hz, 1 H), 3.12 (m, 1 H), 3.50 (m, 1 H), 3.63 (m, 1 H), 6.28 (s, 1 H), 6.38 (s, 1 H), 6.48 (s, 1 H), 6.80 (dd, *J* = 1.2, 7.6 Hz, 1 H), 7.00 (dt, *J* = 1.2, 7.6 Hz, 1 H), 7.18 (dt, *J* = 1.6, 8.0 Hz, 1 H), 7.23 (d, *J* = 7.2 Hz, 1 H); <sup>13</sup>C NMR  $\delta$  d 18.1, 18.9, 19.2, 29.1, 37.0, 59.8, 115.0, 116.3, 120.6, 123.3, 127.0, 131.1; u 25.5, 27.1, 27.9, 32.9, 35.3, 42.9, 55.2, 12.8 Hz, 1 H) and the spiroheterose of the spiroheter

124.5, 127.6, 129.4, 129.9, 130.3, 146.5, 150.8, 169.1; IR (neat): 3385, 3289, 2935, 2874, 1646, 1620, 1518 cm<sup>-1</sup>;HRMS (ESI) *m/z* calcd for C<sub>27</sub>H<sub>33</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 429.2654, found 429.2654.



#### ID CMC-34-157-D5 File KF090408L20 Date 04-Sep-2008 Time 15:53:46 Description MDF009401

**3'-(Cyclohexylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{21}**. General procedure B afforded the spiroheterocycle 14{21} (24 mg, 0.06 mmol, 17% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>35</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 407.2811, found 407.2828.



### ID CMC-34-076-A1 File KF071008L26 Date 10-Jul-2008 Time 21:48:58 Description MDF008636

3'-(Cyclohexylamino)-7'-nitro-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1hi]indole-9,2'-quinoxalin]-4(2H)-one 14{22}. General procedure B afforded the

spiroheterocycle **14***{22}* (69 mg, 0.15 mmol, 45% yield) as a red solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 452.2662, found 452.2667.



### ID CMC-34-076-A2 File KF071008L27 Date 10-Jul-2008 Time 22:01:17 Description MDF008638



7'-Chloro-3'-(cyclohexylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{23}. General procedure B afforded the spiroheterocycle 14{23} (74 mg, 0.17 mmol, 50% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>34</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 441.2421, found 441.2435.





### 6',7'-Dichloro-3'-(cyclohexylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-

spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{24}. General procedure B

afforded the spiroheterocycle **14***{24}* (24 mg, 0.051 mmol, 15% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 475.2031, found 475.2031.



### ID CMC-34-076-A4 File KF071008L04 Date 10-Jul-2008 Time 22:25:55 Description MDF008643

**3'-(Cyclohexylamino)-6',7'-dimethyl-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{25}**. General procedure B afforded the spiroheterocycle **14{25}** (58 mg, 0.13 mmol, 40% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>39</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 435.3124, found 435.3137.



#### ID CMC-34-076-A5 File KF071008L05 Date 10-Jul-2008 Time 22:38:14 Description MDF008647

### 7,7-Dimethyl-3'-((2,4,4-trimethylpentan-2-yl)amino)-31,5,6,7,7a,8,10,10a-octahydro-

**1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{26}*. General procedure B afforded the spiroheterocycle **14***{26}* (66 mg, 0.14 mmol, 42% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>41</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 437.3280, found 437.3290.

### ID CMC-34-076-B1 File KF071008L06 Date 10-Jul-2008 Time 22:50:34 Description MDF008650





7'-Nitro-3'-((2,4,4-trimethylpentan-2-yl)amino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'Hspiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{27}. General procedure B afforded the spiroheterocycle 14{27} (71 mg, 0.15 mmol, 44% yield) as a red solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>40</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 482.3131, found 482.3124.



ID CMC-34-076-B2 File KF071008L07 Date 10-Jul-2008 Time 23:02:53 Description MDF008652

7'-Chloro-3'-((2,4,4-trimethylpentan-2-yl)amino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'Hspiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{28}. General procedure B afforded the spiroheterocycle **14***{28}* (95 mg, 0.20 mmol, 60% yield) as a yellow solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>40</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 471.2891, found 471.2900.



ID CMC-34-076-B3 File KF071008L08 Date 10-Jul-2008 Time 23:15:12 Description MDF008655

6',7'-Dichloro-3'-((2,4,4-trimethylpentan-2-yl)amino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{29}. General procedure B afforded the spiroheterocycle 14{29} (78 mg, 0.15 mmol, 46% yield) as a light brown solid. HRMS (ESI) m/z calcd for C<sub>27</sub>H<sub>39</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 505.2501, found 505.2503.



### ID CMC-34-076-B4 File KF071008L09 Date 10-Jul-2008 Time 23:27:32 Description MDF008658

### 6',7'-Dimethyl-3'-((2,4,4-trimethylpentan-2-yl)amino)-31,5,6,7,7a,8,10,10a-octahydro-

1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{30}. General procedure

B afforded the spiroheterocycle 14{30} (96 mg, 0.21 mmol, 61% yield) as a tan solid. HRMS

(ESI) m/z calcd for C<sub>29</sub>H<sub>45</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 465.3593, found 465.3615.



ID CMC-34-076-B5 File KF071008L10 Date 10-Jul-2008 Time 23:39:51 Description MDF008661



**3'-(Benzylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'quinoxalin]-4(2H)-one 14***{31}*. General procedure B afforded the spiroheterocycle **14***{31}* (56 mg, 0.135 mmol, 40% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>31</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 415.2498, found 415.2512.



NH

**3'-(Benzylamino)-7'-nitro-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{32}*. General procedure B afforded the spiroheterocycle **14***{32}* (42 mg, 0.092 mmol, 27% yield) as a reddish brown solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>30</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 460.2349, found 460.2378.

ID CMC-34-076-C2 File KF071008L12 Date 11-Jul-2008 Time 00:04:30 Description MDF008667



**3'-(Benzylamino)-7'-chloro-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{33}*. General procedure B afforded the spiroheterocycle **14***{33}* (84 mg, 0.188 mmol, 55% yield) as a tan solid. HRMS (ESI) *m/z* calcd for  $C_{26}H_{30}CIN_4O([M+H]^+)$  449.2108, found 449.2095.





# 3'-(Benzylamino)-6',7'-dichloro-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1hi]indole-9,2'-quinoxalin]-4(2H)-one 14{34}. General procedure B afforded the

spiroheterocycle **14***{34}* (46 mg, 0.096 mmol, 28% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 483.1718, found 483.1729.

### ID CMC-34-076-C4 File KF071008L14 Date 11-Jul-2008 Time 00:29:08 Description MDF008671





**3'-(Benzylamino)-6',7'-dimethyl-31,5,6,7,7a,8,10,10a-octahydro-1H,1'Hspiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{35}*. General procedure B afforded the spiroheterocycle **14***{35}* (79 mg, 0.178 mmol, 53% yield) as a tan solid. HRMS (ESI) m/z calcd for C<sub>28</sub>H<sub>35</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 443.2811, found 443.2814.





3'-(o-Tolylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'quinoxalin]-4(2H)-one 14{36}. General procedure B afforded the spiroheterocycle 14{36} (34

mg, 0.082 mmol, 24% yield) as a tan solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.13 (t, *J* = 11.6 Hz, 1 H), 1.43 (t, *J* = 13.6 Hz, 1 H), 1.54-1.63 (complex, 3 H), 1/71-1.88 (complex, 3 H), 2.15 (s, 3 H), 2.31 (m, 1 H), 2.40 (ddd, *J* = 2.0, 6.0, 11.2 Hz, 1 H), 2.66 (m, 1 H), 2.73 (m, 1 H), 3.26 (m, 1 H), 3.58 (m, 2 H), 3.85 (m, 2 H), 6.46 (d, *J* = 7.2 Hz, 1 H), 6.49 (m, 1 H), 6.71 (m, 2 H), 6.82 (m, 2 H), 7.02 (dt, *J* = 1.2, 7.2 Hz, 1 H), 7.22 (m, 2 H); <sup>13</sup>C NMR  $\delta$  d 18.2, 33.5, 40.1, 60.9, 113.8, 114.9, 119.6, 120.7, 122.4, 123.4, 127.1, 131.2; u 18.3, 28.9, 34.2, 35.6, 36.9, 39.4, 47.3, 55.7, 126.6, 129.5, 132.4, 146.4, 151.0, 175.4; IR 3397, 3289, 2928, 1648, 1617, 1609, 1594, 1506 cm<sup>-1</sup>; HRMS (ESI) *m/z* calcd for C<sub>26</sub>H<sub>31</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 415.2498, found 415.2513.

```
ID CMC-34-076-D1 File KF071008L16 Date 11-Jul-2008 Time 00:53:47 Description MDF008678
```



7'-Nitro-3'-(o-tolylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1hi]indole-9,2'-quinoxalin]-4(2H)-one 14{37}. General procedure B afforded the

spiroheterocycle **14***{37}* (9 mg, 0.020 mmol, 6% yield) as a reddish brown solid. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>30</sub>N<sub>5</sub>O<sub>3</sub> ([M+H]<sup>+</sup>) 460.2349, found 460.2350.



ID CMC-34-076-D2 File KF071008L17 Date 11-Jul-2008 Time 01:06:06 Description MDF008711

7'-Chloro-3'-(o-tolylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino]3,2,1hi]indole-9,2'-quinoxalin]-4(2H)-one 14{38}. General procedure B afforded the spiroheterocycle 14{38} (37 mg, 0.082 mmol, 24% yield) as a yellow solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.13 (t, *J* = 12.8 Hz, 1 H), 1.44 (m, 1 H), 1.53-1.71 (complex, 5 H), 1.75-1.88 (complex, 3 H), 2.14 (s, 3 H), 2.27-2.41 (m, 2 H), 2.64-2.73 (m, 2 H), 3.24 (m, 1 H), 3.57 (dt, *J* = 6.4, 16.0 Hz, 1 H), 3.82 (br s, 1 H), 3.85 (m, 1 H), 3.26 (m, 1 H), 6.49 (m, 1 H), 6.50 (d, *J* = 2.0 Hz, 1 H), 6.61 (d, *J* = 8.0 Hz, 1 H), 6.65 (m, 1 H), 6.78 (m, 1 H), 7.03 (t, *J* = 7.2 Hz, 1 H), 7.22 (m, 1 H); <sup>13</sup>C NMR  $\delta$  d 33.5, 40.1, 41.1, 60.9, 113.8, 115.7, 120.5, 122.0, 123.8, 127.2, 131.3; u 18.4, 28.9, 34.1, 35.6, 36.8, 39.4, 47.4, 55.8, 124.3, 129.3, 131.1, 141.4, 146.1, 154.2, 175.4; IR

# 3300, 3268, 2940, 1656, 1596, 1505 cm<sup>-1</sup>; HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>30</sub>ClN<sub>4</sub>O ([M+H]<sup>+</sup>) 449.2108, found 449.2116.

### ID CMC-34-076-D3 File KF071008L18 Date 11-Jul-2008 Time 01:18:25 Description MDF008691



6',7'-Dichloro-3'-(o-tolylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{39}. General procedure B afforded the spiroheterocycle  $14{39}$  (23 mg, 0.048 mmol, 14% yield) as a tan solid. HRMS (ESI) *m/z* calcd for C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 483.1718, found 483.1702.



ID CMC-34-076-D4 File KF071008L19 Date 11-Jul-2008 Time 01:30:44 Description MDF008683

6',7'-Dimethyl-3'-(o-tolylamino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-

**spiro[azepino]3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{40}*. General procedure B afforded the spiroheterocycle **14***{40}* (52 mg, 0.118 mmol, 35% yield) as a tan solid. Mp = 243-248 °C (dec); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.10 (t, *J* = 12.8 Hz, 1 H), 1.39 (t, *J* = 12.8 Hz, 1 H), 1.51-1.62 (m, 3 H), 1.72-1.82 (complex, 4 H), 2.09 (s, 3 H), 2.14 (s, 3 H), 2.15 (s, 3 H), 2.30 (m, 1 H), 2.38 (ddd, *J* = 2.4, 7.6, 14.0 Hz, 1 H), 2.63 (m, 1 H), 2.68 (m, 1 H), 3.25 (m, 1 H), 3.57 (dt, *J* = 6.4, 12.0 Hz, 1 H), 3.82 (m, 1 H), 3.85 (m, 1 H), 6.29 (s, 1 H), 6.35 (s, 1 H), 6.49 (s, 1 H), 6.80 (dd, *J* = 1.2, 7.6 Hz, 1 H), 7.00 (dt, *J* = 1.2, 7.6 Hz, 1 H), 7.19 (dt, *J* = 1.2, 7.6 Hz, 1 H), 7.23 (d, *J* = 7.2 Hz); <sup>13</sup>C NMR  $\delta$  d 18.2, 18.9, 19.2, 33.5, 40.1, 61.1, 115.1, 116.5, 120.8, 123.4, 127.1, 131.2; u 18.4, 28.9, 34.1, 35.7, 36.9, 39.4, 47.4, 55.8, 124.6, 127.6, 129.5, 130.2, 130.4, 146.7, 151.3,

175.4; IR 3311, 2928, 2861, 1644, 1615, 1592, 1516 cm<sup>-1</sup>; HRMS (ESI) m/z calcd for C<sub>28</sub>H<sub>35</sub>N<sub>4</sub>O ([M+H]<sup>+</sup>) 443.2811, found 443.2798.



ID CMC-34-076-D5 File KF071008L20 Date 11-Jul-2008 Time 01:43:03 Description MDF008688

### ((4-Methoxyphenyl)amino)-7'-nitro-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-

**spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{41}*. A reaction vial was charged with a magnetic stir bar, ketoamide **8b** (50 mg, 0.24 mmol), diamine fragment **13b** (44 mg, 0.29 mmol, 1.2 equiv.) and *p*-toluenesulfonic acid (5 mg, 0.024 mmol, 0.1 equiv.). A solution of isonitrile **12e** (38 mg, 0.29 mmol, 1.2 equiv.) in EtOH (2.0 mL) was added via syringe through the septum cap and the reaction stirred for 14 h at rt. Water (7 mL) was added to precipitate the products. The reaction mixture was filtered and the collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL). The crude product was purified by chromatography on silica gel

to afford the spiroheterocycle **14***{41}* (79 mg, 0.166 mmol, 69% yield) as a red-brown solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.31 (m, 1 H), 1.47-1.62 (complex, 5 H), 1.75-1.88 (complex, 3 H), 2.35 (m, 2 H), 2.62 (m, 2 H), 3.23 (m, 1 H), 3.56 (m, 1 H), 3.83 (s, 3 H), 3.84 (m, 2 H), 5.20 (s, 1 H), 6.53 (d, *J* = 8.8 Hz, 1 H), 6.84 (m, 2 H), 6.94 (m, 2 H), 7.04 (br s, 1 H), 7.62 (m, 2 H); <sup>13</sup>C NMR  $\delta$  d 33.3, 39.8, 55.5, 60.8, 109.8, 112.8, 115.2 (× 2), 115.6, 122.0 (× 2); u 18.3, 28.8, 34.0, 35.7, 36.0, 47.3, 55.4, 133.1, 140.1, 142.5, 150.8, 156.2, 175.2; IR 3335, 2929, 2855, 1612, 1524, 1502 cm<sup>-1</sup>; HRMS calcd for C<sub>26</sub>H<sub>30</sub>N<sub>5</sub>O<sub>4</sub> [M + H<sup>+</sup>] 476.2298, found 476.2292.



((4-Methoxyphenyl)amino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{42}. A reaction vial was charged with a magnetic stir bar, ketoamide 8b (50 mg, 0.24 mmol), diamine fragment 13c (41 mg, 0.29 mmol, 1.2 equiv.) and *p*-toluenesulfonic acid (5 mg, 0.024 mmol, 0.1 equiv.). A solution of isonitrile 12e (38 mg, 0.29 mmol, 1.2 equiv.) in EtOH (2.0 mL) was added via syringe through the septum cap and the reaction stirred for 14 h at rt. Water (7 mL) was added to precipitate the products. The reaction mixture was filtered and the collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL). The crude product was purified by chromatography on silica gel to afford the spiroheterocycle 14{42} (81 mg, 0.174 mmol, 73% yield) as a pink solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.12 (t, *J* = 12.8 Hz, 1 H), 1.41 (t, *J* = 13.2 Hz, 1 H), 1.58 (m, 1 H), 1.64 (m, 2 H), 1.75-1.86 (complex, 3 H), 2.33 (m, 2 H), 2.62 (m, 2 H), 3.22 (m, 1 H), 3.54 (m, 1 H), 3.82 (s, 3

H), 3.87 (m, 3 H), 6.51 (d, J = 2.0 Hz, 1 H), 6.63 (m, 2 H), 6.76 (dd, J = 2.0, 8.4 Hz, 1 H), 6.81 (d, J = 2.0 Hz, 1 H), 6.83 (t, J = 2.4 Hz, 2 H), 6.93 (m, 2 H); <sup>13</sup>C NMR  $\delta$  d 33.4, 40.0, 55.6, 61.0, 113.7, 115.2 (× 2), 115.7, 121.9, 122.2 (× 2); u 18.4, 28.9, 34.1, 35.7, 36.5, 39.4, 47.4, 55.6, 124.2, 127.7, 131.2, 140.7, 151.5, 156.0, 175.4; IR 3287, 2928, 2873, 1604, 1571, 1515 cm<sup>-1</sup>; HRMS calcd for C<sub>26</sub>H<sub>30</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H<sup>+</sup>] 465.2057, found 465.2050.



**6',7'-Dichloro-3'-((4-methoxyphenyl)amino)-31,5,6,7,7a,8,10,10a-octahydro-1H,1'H-spiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14***{43}*. A reaction vial was charged with a magnetic stir bar, ketoamide **8b** (50 mg, 0.24 mmol), diamine fragment **13c** (41 mg, 0.29 mmol, 1.2 equiv.) and *p*-toluenesulfonic acid (5 mg, 0.024 mmol, 0.1 equiv.). A solution of isonitrile **12e** (38 mg, 0.29 mmol, 1.2 equiv.) in EtOH (2.0 mL) was added via syringe through the septum cap and the reaction stirred for 14 h at rt. Water (7 mL) was added to precipitate the
products. The reaction mixture was filtered and the collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL). The crude product was purified by chromatography on silica gel to afford the spiroheterocycle **14***{43}* (27 mg, 0.055 mmol, 23% yield) as a light brown solid. Mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.15 (t, *J* = 13.2 Hz, 1 H), 1.40-1.68 (complex, 4 H), 1.75-1.87 (complex, 4 H), 2.31 (m, 1 H), 2.62 (m, 2 H), 3.22 (m, 1 H), 3.52 (m, 1 H), 3.82 (s, 3 H), 3.84 (m, 2 H), 6.59 (s, 1 H), 6.67 (br s, 1 H), 6.78 (m, 1 H), 6.79 (m, 1 H), 6.82 (m, 1 H), 6.91 (t, *J* = 2.8 Hz, 1 H), 6.94 (m, 1 H); <sup>13</sup>C NMR  $\delta$  d 33.3, 39.8, 55.5, 60.8, 114.7, 115.2 (× 2), 115.7, 122.0 (× 2); u 18.3, 28.8, 34.1, 35.7, 36.2, 39.3, 47.3, 55.6, 121.7, 124.7, 126.4, 132.5, 140.5, 151.1, 156.0, 175.3; IR 3289, 2929, 2877, 1606, 1574, 1515 cm<sup>-1</sup>; HRMS calcd for C<sub>26</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H<sup>+</sup>] 499.1668, found 499.1664.

Sample 3 Vial 4:40 ID CMC-34-042-D File KF041808L03 Date 21-Apr-2008 Time 21:34:37 Description







3'-((4-Methoxyphenyl)amino)-6',7'-dimethyl-31,5,6,7,7a,8,10,10a-octahydro-1H,1'Hspiro[azepino[3,2,1-hi]indole-9,2'-quinoxalin]-4(2H)-one 14{44}. A reaction vial was charged with a magnetic stir bar, ketoamide 8b (50 mg, 0.24 mmol), diamine fragment 13e (39 mg, 0.29 mmol, 1.2 equiv.) and p-toluenesulfonic acid (5 mg, 0.024 mmol, 0.1 equiv.). A solution of isonitrile 12e (38 mg, 0.29 mmol, 1.2 equiv.) in EtOH (2.0 mL) was added via syringe through the septum cap and the reaction stirred for 14 h at rt. Water (7 mL) was added to precipitate the products. The reaction mixture was filtered and the collected precipitate was washed with NaOH (0.5 N, 2 mL) and water (3 mL). The crude product was purified by chromatography on silica gel to afford the spiroheterocycle 14{44} (78 mg, 0.170 mmol, 71% yield) as a light brown solid. TLC  $R_f = 0.54$  (50% acetone in CH<sub>2</sub>Cl<sub>2</sub>); mp > 260 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.08 (t, J = 11.6 Hz, 1 H), 1.36 (m, 1 H), 1.55 (m, 2 H), 1.70-1.82 (m, 3 H), 2.09 (s, 3 H), 2.14 (s, 3 H), 2.32 (m, 2 H), 2.62 (m, 2 H), 3.23(m, 1 H), 3.50 (m, 1 H), 3.56 (m, 1 H), 3.81 (s, 3 H), 3.83 (m, 1 H), 5.30 (s, 1 H), 6.29 (s, 1 H), 6.49 (m, 2 H), 6.82 (d, J = 8.8 Hz, 1 H), 6.92 (d, J = 8.8 Hz, 2 H); <sup>13</sup>C NMR  $\delta$  d 18.9, 19.2, 33.4, 39.9, 55.5, 61.0, 115.0, 115.1 (× 2), 116.4, 122.3 (× 2); u 18.3, 28.8, 34.0, 35.7, 36.5, 39.3, 47.3, 55.6, 124.5, 127.5, 130.0, 130.2, 141.3, 152.3, 155.7, 175.3; IR 3294, 2927, 2857, 1640, 1611, 1500 cm<sup>-1</sup>; HRMS calcd for  $C_{28}H_{35}N_4O_2$  [M + H<sup>+</sup>] 459.2760, found 459.2728.



0

Ēt

N<sub>3</sub>



















































S-97









S-101



<sup>ii</sup> Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.; Roth, B. L.; Mailman, R.
 (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
 *Neuropsychopharmacology* 28, 1400-1411.

<sup>iii</sup> Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B.
(2002) Salvinorin A: a Potent Naturally Occurring Nonnitrogenous Kappa Opioid Selective Agonist. *Proc. Natl. Acad. Sci. U.S.A.* 99, 11934-11939.

<sup>iv</sup> Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc. Natl. Acad. Sci.USA* **104**, 5163-5168.

<sup>&</sup>lt;sup>i</sup> Frankowski, K. J.; Neuenswander, B.; Aubé, J. (2008) Explorations of *Stemona* alkaloid-inspired analogues: skeletal modification and functional group diversification. *J. Comb. Chem.* **10**, 721-725.